Benjamin Cowen

CEO

Dr. Cowen has 20 years of pharmaceutical/biotech experience with a broad background spanning Business Development, Finance, R&D Portfolio Management, Marketing, and Sales. He has also worked across the spectrum including large pharma, mid-sized pharma and small companies.

Currently, Dr. Cowen is CEO at ImmunoMet Therapeutics Inc., a VC funded company utilizing cellular metabolism to develop novel anti-tumor and immuno-metabolism therapies. Dr. Cowen joined ImmunoMet in Nov. 2016 as COO as was promoted to CEO a year later.

Dr. Cowen currently serves on the Board of Directors of INCON, a public Korean company that invests in healthcare companies.

Dr. Cowen originally trained as research scientist and was an NIH Postdoctoral Fellow at the Univ. of Pennsylvania. He holds a BA in Physics with high honors from Brandeis Univ., a PhD in Biophysics from the University of Illinois and an MBA in Strategy and Finance from Carnegie Mellon Univ.